Alnylam Pharmaceuticals is selling off in pre-market trading, continuing a trend that has left the stock 4.9 percent below its 50-day moving average.
There is no company-specific news or regulatory filing from the past 48 hours to explain this downward momentum, as recent reports have focused on broader industry developments such as the FDA approval of Eli Lilly's once-weekly insulin injection and various operational updates from other biotechnology firms. In the ab